Sartorius has bought US purification expert WaterSep BioSeparations LLC through Sartorius Stedim Biotech.
Marlborough, Massachusetts-based WaterSep BioSeparations manufactures hollow-fiber membrane devices and pre-sterilized assemblies for upstream and downstream biopharmaceutical applications. WaterSep BioSeparations’ technology is especially suited to gene and cell therapy applications, vaccine production and intensified bioprocessing.
The privately-owned company employs around 15 people and is expected to have revenue of around US$2.5 million in 2020.
The agreed purchase price is approximately US$27 million plus an earn-out of up to US$9 million, depending on the defined sales revenue growth by 2023.
The acquisition complements Sartorius’s separation portfolio, adding crossflow filtration units for easy-to-use bioprocessing devices.
“This acquisition nicely complements our current offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing,” said Dr René Fáber, head of the Sartorius Bioprocess Solutions Division and executive board member. “I am pleased to welcome the WaterSep team to Sartorius and look forward to jointly introducing WaterSep BioSeparations innovative solutions to our customers.”
“With Sartorius’ strong emphasis on cost- and time-saving bioprocessing, it is the ideal partner to accelerate the adoption of our extensive single-use crossflow product offerings. WaterSep is excited to join the Sartorius team as they continue to lead the transformation of bioprocessing to single use,” said Attila Herczeg, CEO and president of WaterSep BioSeparations.
